Navigation Links
Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease

HORSHAM, Pa. and KENILWORTH, N.J., Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has approved a new indication for REMICADE(R) (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies.

REMICADE has been studied only in combination with conventional immunosuppressive therapy. This approval follows a positive opinion granted in March by the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMEA).

"Crohn's disease significantly impacts the quality of life of children suffering from this condition," said Salvatore Cucchiara, M.D., Department of Pediatrics, Gastrointestinal Motility and Endoscopy Unit, University of Naples. "Infliximab provides physicians with a new treatment option that addresses the unique aspects of this difficult-to-treat disease in the pediatric population."

REMICADE is the first and only biologic therapy approved in the EU for the treatment of pediatric CD, a debilitating condition that causes inflammation of the gastrointestinal tract, typically resulting in symptoms such as diarrhea, fever, abdominal pain, weight loss and in some patients, delayed development and stunted growth.

"This approval recognizes the unique value of REMICADE as it is the first and only biologic therapy available to children suffering with Crohn's disease in Europe, who previously had limited therapy options," said Robert J. Spiegel, M.D., chief medical officer, Schering-Plough Research Institute.

In May 2006, the United States Food and Drug Administration (FDA) approved REMICADE for pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy. REMICADE was first approved in the U.S. for adult Crohn's disease in 1998 and later for adult ulcerative colitis in 2005.

The safety and efficacy of REMICADE across all indications have been well established in clinical trials over the past 14 years and through commercial experience with nearly 925,000 patients treated worldwide across all indications.

The label extension will permit physicians to administer a 5 mg/kg intravenous infusion of REMICADE over a 2-hour period followed by additional 5 mg/kg infusion doses at two and six weeks after the first infusion, then every eight weeks thereafter.

Some patients may require a shorter dosing interval to maintain clinical benefit, while for others a longer dosing interval may be sufficient. Available data do not support further REMICADE treatment in pediatric patients not responding within the first 10 weeks of treatment.


'"/>




Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and ... this old family recipe, which is meant to relieve gout and pain caused by ... a 12-hour energy boost every time. It relieved what VA doctors called the worst ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... proudly announced today that a new solution for Emergency Departments (ED) has been ... tight space in Emergency Department examination rooms, and with a simplified pallet of ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: